To compare the effect of intravenous sugammadex(intervention group) vs neostigmine with glycopyrrolate on post operative nausea and vomiting in adults undergoing ear,nose and throat surgery under general anaesthesia

A COMPARATIVE STUDY OF EFFECT OF INTRAVENOUS SUGAMMADEX AND NEOSTIGMINE WITH GLYCOPYRROLATE ON POSTOPERATIVE NAUSEA AND VOMITING IN ADULT PATIENTS UNDERGOING OTORHINOLARYNGEAL SURGERY UNDER GENERAL ANAESTHESIA - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/107033

Enrollment

102

Registered

2026-03-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Sugammadex: Patients will recieve 2mg/kg of intravenous sugammadex at the time of neuromuscular blockade reversal Control Intervention1: Neostigmine with glycopyrrolate: Patients will r

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 to 65 years. Patients belonging to either of the gender - male or female. Patients belonging to American society of Anaesthesiology (ASA) grade I and II. Patients willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: Patients with known allergies to rocuronium, neostigmine or sugammadex. Patients who are pregnant. Patients with impaired Renal function. Patients having body mass index of more than 30. Patients having history of postoperative nausea and vomiting and motion sickness .

Design outcomes

Primary

Measure	Time frame
To compare the effect of sugammadex and neostigmine with glycopyrrolate on post operative nausea and vomiting in adult patients undergoing otorhinolaryngeal surgery under general anaesthesiaTimepoint: Post operative nausea and vomiting will be assessed in patients upon arrival in recovery room and subsequently at an intervals of 1 hour,6 hours and 12 hours of post reversal.	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Amanjot Singh

Guru Gobind Singh Medical College and Hospital Faridkot Punjab India

amanjotrajpal@ggsmch.org9041221142

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026